Ascendiant Capital Starts Echo Therapeutics (ECTE) at Buy
Tweet
Share
E-mailGet Alerts ECTE Hot Sheet
Price: $0.00 --0%
Rating Summary:
5 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Rating Summary:
5 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Join SI Premium – FREE
Ascendiant Capital initiates coverage on Echo Therapeutics (NASDAQ: ECTE) with a Buy. PT $2.00.
The firm is calling ECTE, "an intriguing continuous glucose monitor play."
"We anticipate that Echo will commence a 50 patient pivotal study of the Symphony device around the end of this year, intended to obtain the CE Mark for the device by the end of 2013. We would then expect the Company to conduct a subsequent pivotal study in the U.S. designed to achieve FDA approval, which we estimate could be secured in 2015."
For an analyst ratings summary and ratings history on Echo Therapeutics click here. For more ratings news on Echo Therapeutics click here.
Shares of Echo Therapeutics closed at $1.47 yesterday.
The firm is calling ECTE, "an intriguing continuous glucose monitor play."
"We anticipate that Echo will commence a 50 patient pivotal study of the Symphony device around the end of this year, intended to obtain the CE Mark for the device by the end of 2013. We would then expect the Company to conduct a subsequent pivotal study in the U.S. designed to achieve FDA approval, which we estimate could be secured in 2015."
For an analyst ratings summary and ratings history on Echo Therapeutics click here. For more ratings news on Echo Therapeutics click here.
Shares of Echo Therapeutics closed at $1.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Craig-Hallum Starts Alterity Therapeutics (ATHE) at Buy
- Goldman Sachs Starts Autodesk (ADSK) at Neutral
- Compass Point Starts Sonida Senior Living (SNDA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
